The two transgenic double APP/PS1 transgenic models display distinct age-dependent progression and severity of amyloid plaque burden [30,36–40], allowing for the assessment of effects of liraglutide administration in the context of differential APP/PS1 mutation-induced β-amyloid overexpression and associated cognitive deficits. This evidence concerns the gene PSEN1 and amyloidosis.